Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 2/20 | 0.47 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 4/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2385485 | 0.95 | ITGA4 (0.49) | ITGA4ITGB7ACECTSSCTSK | |
| SCHEMBL2385019 | 0.92 | ITGA4 (0.44) | ITGA4ITGB7MDM4MDM2ACE | |
| SCHEMBL2388324 | 0.92 | ATM (0.47) | ITGA4ITGB7ACECTSSCTSK | |
| SCHEMBL2385034 | 0.92 | ITGA4 (0.45) | ITGA4ITGB7ACECTSSCTSK | |
| SCHEMBL2386287 | 0.91 | ITGA4 (0.45) | ITGA4ITGB7MDM4MDM2ACE | |
| SCHEMBL2386710 | 0.91 | KMT2A (0.47) | ITGA4ITGB7ACEKLK5PPARA | |
| SCHEMBL2385864 | 0.91 | ALDH1A1 (0.48) | ITGA4ITGB7MDM4MDM2ACE | |
| SCHEMBL2385221 | 0.90 | PPARG (0.52) | ACEMME | |
| SCHEMBL2387117 | 0.90 | ITGA4 (0.44) | ITGA4ITGB7ACECTSSCTSK | |
| SCHEMBL2385571 | 0.90 | ITGA4 (0.44) | ITGA4ITGB7ACECTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017378-B2 | Method for production of optically active biphenylalanine compound or salt or ester thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-09-13 | — | — | US | disclosed |
| EP-1980622-B1 | METHOD FOR PRODUCTION OF AN OPTICALLY ACTIVE BIPHENYLALANINE COMPOUND OR SALT OR ESTER THEREOF | SUMITOMO CHEMICAL CO (JP) | 2010-08-18 | — | — | EP | disclosed |
| US-20090011475-A1 | Method For Production of Optically Active Biphenylalanine Compound or Salt or Ester Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1980622-A1 | METHOD FOR PRODUCTION OF OPTICALLY ACTIVE BIPHENYLALANINE COMPOUND OR SALT OR ESTER THEREOF | Sumitomo Chemical Company, Limited (JP) | 2008-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090011475-A1 | Method For Production of Optically Active Biphenylalanine Compound or Salt or Ester Thereof | DNPEP, APEH, PAH | ITGA4 4819/4885ITGB7 4625/4885MDM4 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.